



Accelerating
Diagnosis, Treatments, and a Cure
for
Celiac Disease

2018

ANNUAL
REPORT

ACCELERATING RESEARCH

Strategic investments in cutting-edge biomedical research and patient engagement to advance the pursuit of treatments and a cure for celiac disease.

Driving Innovation



iCureCeliac® is the nation's largest public patient registry for celiac disease.



iQualifyCeliac is the only patient-driven celiac disease clinical trial screening tool.

Advancing Therapeutic Treatment Development

iCureCeliac® empowers celiac patients to share their medical information and experiences to shape the future of celiac research.

6,312  TOTAL REGISTRANTS in iCureCeliac®

iQualifyCeliac Trial Screening Tool speeds participation in clinical trials to advance the development of better treatments and a cure for celiac disease.

8  NUMBER OF CLINICAL TRIALS for which the Foundation has recruited patients

PROMOTING EDUCATION

Outreach to patients and healthcare providers has improved the diagnostic rate for celiac disease. Focused investments must continue to further close the gap and end the needless suffering of millions.

Impacting Patients



is the primary patient education vehicle for celiac disease.

6.5  MILLION CELIAC.ORG visitors annually

3.6  MILLION SYMPTOMS checklist users

Educating Providers to Improve Care

NASPGHAN online diagnostic tool helps physicians diagnose celiac disease.

7,200+  PHYSICIANS EDUCATED

Children's National Celiac Disease and Psychological Health Program educates providers on diagnosing celiac disease and its psychological impact.

285  PROVIDERS EDUCATED

Celiac Disease Internal Medicine Residency Training Program, at the Keck School of Medicine of USC, trains new physicians in the recognition and treatment of celiac disease.

110+  RESIDENTS EDUCATED

EFFECTIVE ADVOCACY

Committed to being the worldwide voice of the celiac community before key policy makers in Congress and federal research and regulatory agencies.

Expanding Reach

Granted North American affiliate membership in the **Association of European Coeliac Societies (AOECS)** to promote awareness and research worldwide.

Patient-Centered Outcomes Research Institute (PCORI) National Patient Engagement Advisory Panel appointment of Marilyn G. Geller, CEO.

Giving Voice to the Celiac Community

The **Patient Advocate Program** prepares participants to engage in celiac disease research and public advocacy.

1,100+  TRAINED PARTICIPANTS

The Foundation collaborates on federal initiatives to support patient protections of chronic disease.

8  INITIATIVES EXECUTED in past 12 months

ASSETS

Cash	\$ 1,095,414
Grants Receivable	\$ 164,659
Accounts Receivable	\$ 142,500
Prepaid Expenses	\$ 17,801
Deposits	\$ 9,210
Property and Equipment	\$ 86,041

Total Assets	\$ 1,515,625
---------------------	---------------------

LIABILITIES

Accounts Payable	\$ 116,710
Accrued Vacation	\$ 36,311
Unearned Revenue	\$ 200,957

Total Liabilities	\$ 353,978
--------------------------	-------------------

NET ASSETS

Unrestricted	\$ 1,161,647
--------------	--------------

Total Liabilities and Net Assets	\$ 1,515,625
---	---------------------

OPERATING SUPPORT

Contributions and Grants	\$ 571,851
Annual Meeting	\$ 72,770
Gifts in Kind	\$ 292,092
Sponsorships, Program Income and Special Events	\$ 746,250

Total Revenue	\$ 1,682,963
----------------------	---------------------

OPERATING EXPENSES

Program Expenses	\$ 1,151,147
Management and General	\$ 66,540
Development	\$ 50,591

Total Expenses	\$ 1,268,278
-----------------------	---------------------

Change in Net Assets	\$ 414,685
-----------------------------	-------------------